From willow bark to mosquitoes, nature has been a source of vital medications for centuries. But species die-off caused by human activity is putting this at risk What will biodiversity loss mean for drug discovery?Traditionally used as a painkiller for…
Digital therapeutics startup Neuroglee raises $10M to help people with neurodegenerative conditions
Neuroglee Therapeutics, a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10 million Series A led by Openspace Ventures and EDBI. The funding will be used to launch virtual neurology clinics and to support Neuroglee’s move to Boston. Other participants included Ramen Singh, the former chief executive officer of Mundipharma; Biofourmis […]
‘Anthony Hopkins committed within five minutes’: how I wrote The Father with Florian Zeller
After Christopher Hampton saw Zeller’s dementia drama on stage in Paris, neither language, finance nor another film adaptation could thwart their collaboration on the screenplayI first met Florian Zeller about eight years ago. It was in the foyer of th…
Streaming: The Father and other films about dementia
Florian Zeller’s heart-rending film The Father is the latest in a spate of recent works tackling the condition and its effects on the familyFirst shown way back at Sundance in January last year, and repeatedly delayed by the pandemic, The Father waited…
Dementia risk lower for people in stimulating jobs, research suggests
Findings of large study support the idea mental stimulation could delay onset of symptoms, says lead authorPeople with mentally stimulating jobs have a lower risk of dementia in later years than those who have non-stimulating work, research has suggest…
Artificial intelligence could be used to diagnose dementia
Researchers say AI tool could lead to earlier diagnoses that could improve patients’ outcomesIt’s been used to detect eye diseases, make medical diagnoses, and spot early signs of oesophageal cancer. Now it has been claimed artificial intelligence may …
Maker of dubious $56K Alzheimer’s drug offers cognitive test no one can pass
After facing intense criticism, Biogen goes on defense, blames “misinformation.”